| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/12/2009 | US20090041786 e.g. 5-Fluoro-N4-(3-hydroxyphenyl)-N2-[4-(N-methyl)aminosulfonyl-3-methoxyphenyl]-2,4-pyrimidinediamine; tyrosine (JAK) kinases inhibitor; interleukin and tumor necrosis factor ligand; transplant rejection; T-cell mediated autoimmune disease |
| 02/12/2009 | US20090041779 Aldosterone induced elastin production |
| 02/12/2009 | US20090041778 Methods And Compositions For The Treatment Of Graft Failure |
| 02/12/2009 | US20090041777 G-protein specific immunoglobulin targeting and treatment of viral disorders; Drug screening |
| 02/12/2009 | US20090041774 Haemophilus influenzae type IV pili |
| 02/12/2009 | US20090041764 Methods for the treatment of muscular dystrophy associated with dysferlin-deficiency |
| 02/12/2009 | US20090041760 Retroviral immunotherapy |
| 02/12/2009 | US20090041759 Materials and methods for treating ocular-related disorders |
| 02/12/2009 | US20090041757 Bone morphogenetic protein antagonist and uses thereof |
| 02/12/2009 | US20090041756 121p1f1: a tissue specific protein highly expressed in various cancers |
| 02/12/2009 | US20090041753 Cytokine signaling |
| 02/12/2009 | US20090041751 Sepsis Prevention Through Adenosine Receptor Modulation |
| 02/12/2009 | US20090041747 Compounds for Stabilizing Factor VII Polypeptide Formulations |
| 02/12/2009 | US20090041745 Modulators of paraptosis and related methods |
| 02/12/2009 | US20090041743 Sperm-blocking agent composition with contraceptive effect |
| 02/12/2009 | US20090041742 Human dnase ii |
| 02/12/2009 | US20090041740 Cancer treatment by metabolic modulations |
| 02/12/2009 | US20090041739 Method for treating a pulmonary disease state in mammals by up or down regulating indigenous in vivo levels of inflammatory agents in mammalian cells |
| 02/12/2009 | US20090041738 Method for treating a pulmonary disease state in mammals by up or down regulating indigenous in vivo levels of inflammatory agents in mammalian cells |
| 02/12/2009 | US20090041733 Methods for cell mobilization using in vivo treatment with hyaluronan (ha) |
| 02/12/2009 | US20090041728 Proteoglycan Degrading Mutants for the Treatment of CNS |
| 02/12/2009 | US20090041723 useful in the production of a library of pyrazole derivatives for biological screening; Hepatitis C virus (HCV); ease of crystallization, yield, stability, solubility, hygroscopicity and flowability of the resulting bulk drug |
| 02/12/2009 | US20090041722 Indole indane amide compounds useful as cb2 agonists and method |
| 02/12/2009 | US20090041721 Arylalkoxyl hepatitis c virus protease inhibitors |
| 02/12/2009 | US20090041720 Heteroaryl substituted thiazoles |
| 02/12/2009 | US20090041718 Methods of Modulating Cytokine Activity; Related Reagents |
| 02/12/2009 | US20090041716 Crystalline form of methyl ((1s)-1-(((2s)-2-(5-(4'-(2-((2s)-1((2s)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1h-imidazol-5-yl)-4-biphenylyl)-1h-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt |
| 02/12/2009 | US20090041715 Epothilone Combinations |
| 02/12/2009 | US20090041687 Use of opioid receptor antagonists |
| 02/12/2009 | US20090041685 Cosmetic Delivery System and Process for Manufacture Thereof |
| 02/12/2009 | US20090041682 Medical product |
| 02/12/2009 | US20090041681 Anti-inflammatory inhalation pharmaceutical composition |
| 02/12/2009 | US20090041678 Metronidazole-based dermatological foams and emulsions for the preparation thereof |
| 02/12/2009 | US20090041675 Organic compounds |
| 02/12/2009 | US20090041672 Drug for Treating or Diagnosing Vascular Lesion in the Skin or the Subcutaneous Soft Tissue Caused by Light Irradiation |
| 02/12/2009 | US20090041671 Protein cages for the delivery of medical imaging and therapeutic agents |
| 02/12/2009 | US20090041667 Treatment of Depressive Disorders |
| 02/12/2009 | US20090041666 Ophthalmic formulations of Amyloid-beta contrast agent and methods of use thereof |
| 02/12/2009 | US20090041663 Sigma-2 receptor radiotracers for imaging the proliferative status of solid tumors |
| 02/12/2009 | US20090038612 Medical product containing tiotropium |
| 02/12/2009 | DE112007000920T5 Pharmazeutische Zusammensetzungen von Cefixim Pharmaceutical compositions of cefixime |
| 02/12/2009 | DE102007037932A1 Donepezilhydrochlorid in amorpher Form enthaltende Tablette Donepezil hydrochloride containing amorphous form tablet |
| 02/12/2009 | DE102007037018A1 Composition, useful for treating or caring skin and hair, comprises nitro-carbonyl compound and further e.g. monoalcohol, polyol, diethanolamine, fatty acid, silicon substituted compound and nonionic emulsifier |
| 02/12/2009 | DE102007035642A1 Substanzen zur Protektion von Zellen und Geweben gegen Schädigung durch ungünstige Bedingungen Substances for protection of cells and tissues against damage by unfavorable conditions |
| 02/12/2009 | DE102006047231B4 Substituierte Indeno[1,2-b]indolderivate als neue Hemmstoffe der Protein Kinase CK2 und ihre Verwendung als Tumor Therapeutika, Cytostatika und Diagnostika Substituted indeno [1,2-b] indole derivatives as new inhibitors of protein kinase CK2 and their use as antitumor agents, cytostatic agents and diagnostic agents |
| 02/12/2009 | DE10064219B9 Neue Fentanyl und/oder dessen Derivate enthaltende pharmazeutische Zusammensetzung zur nasalen Anwendung New fentanyl and / or its derivatives containing pharmaceutical composition for nasal administration |
| 02/12/2009 | CA2830727A1 Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid |
| 02/12/2009 | CA2707334A1 A process for the preparation or purification of olmesartan medoxomil |
| 02/12/2009 | CA2707292A1 Powdered medicament for nasal delivery of ascorbic acid for reducing apomorphine induced toxicity to ciliated tissue |
| 02/12/2009 | CA2707030A1 Imidazopyridinones |
| 02/12/2009 | CA2704929A1 Compositions and methods for procedural sedation and analgesia using oral transmucosal dosage forms |
| 02/12/2009 | CA2700733A1 Bupropion hydrobromide and therapeutic applications |
| 02/12/2009 | CA2699461A1 Inhibitors of intracellular urokinase plasminogen activator and methods of use thereof |
| 02/12/2009 | CA2698752A1 Oral cannabinoid liquid formulations and methods of treatment |
| 02/12/2009 | CA2696565A1 6-amino-pyrimidine-4-carboxamide derivatives and related compounds which bind to the sphingosine 1-phosphate (s1p) receptor for the treatment of multiple sclerosis |
| 02/12/2009 | CA2696253A1 Sulfamide derivative useful for the treatment of epilepsy |
| 02/12/2009 | CA2696035A1 Treating or preventing rotavirus infection |
| 02/12/2009 | CA2695864A1 Gamma secretase modulators |
| 02/12/2009 | CA2695857A1 Kinase inhibitors, compositions comprising them, and methods of their use |
| 02/12/2009 | CA2695852A1 Cyclic amine compounds |
| 02/12/2009 | CA2695844A1 Treatments and prevention of hydrocephalus |
| 02/12/2009 | CA2695812A1 Novel 1,2,3-triazole derivatives useful as modulators of nicotinic acetylcholine receptors |
| 02/12/2009 | CA2695729A1 Crystalline form of methyl ((1s)-1-(((2s)-2-(5-(4'-(2-((2s)-1-((2s)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1h-imidazol-5-yl)-4-biphenylyl)-1h-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt |
| 02/12/2009 | CA2695664A1 Phenoxy-pyrrolidine derivative and its use and compositions |
| 02/12/2009 | CA2695621A1 Pyridine carboxamide orexin receptor antagonists |
| 02/12/2009 | CA2695616A1 Antimicrobial ortho-fluorophenyl oxazolidinones for treatment of bacterial infections |
| 02/12/2009 | CA2695580A1 Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors |
| 02/12/2009 | CA2695519A1 Pharmaceutical compositions containing dopamine receptor ligands and methods of treatment using dopamine receptor ligands |
| 02/12/2009 | CA2695505A1 Znf206: a novel regulator of embryonic stem cell self-renewal and pluripotency |
| 02/12/2009 | CA2695461A1 Renin inhibitors |
| 02/12/2009 | CA2695437A1 Aminopyrazole amide derivative |
| 02/12/2009 | CA2695431A1 Fused heterocycles |
| 02/12/2009 | CA2695406A1 Crystalline form of a dihydropteridione derivative |
| 02/12/2009 | CA2695405A1 N-(2-thiazolyl)-amide derivatives for the treatment of obesity, diabetes and cardiovascular diseases |
| 02/12/2009 | CA2695390A1 Hepatitis c antiviral compositions and methods |
| 02/12/2009 | CA2695372A1 Methods for treating dependence |
| 02/12/2009 | CA2695365A1 Method of treating cxcr3 mediated diseases using heterocyclic substituted piperazines |
| 02/12/2009 | CA2695331A1 Pyridinecarboxamide and benzamide derivatives as taar1 ligands |
| 02/12/2009 | CA2695294A1 Use of a material based on a thermoplastic polymer having a high content of antioxidants for packaging dianhydrohexitols |
| 02/12/2009 | CA2695082A1 Peptide boronic acid and boronic ester compounds as proteasome inhibitors |
| 02/12/2009 | CA2695061A1 Sdf-1 binding nucleic acids and the use thereof |
| 02/12/2009 | CA2694881A1 The application of 5-methyl-1,3-benzenediol or derivatives thereof in the preparation of medicines and functional foods for treatment or prevention of depression |
| 02/12/2009 | CA2694140A1 Method for treating a pulmonary disease state in mammals by up or down regulating indigenous in vivo levels of inflammatory agents in mammalian cells |
| 02/12/2009 | CA2694061A1 Gel composition for external application containing an adenine compound |
| 02/12/2009 | CA2693997A1 Viral polymerase inhibitors |
| 02/12/2009 | CA2693495A1 Viral polymerase inhibitors |
| 02/12/2009 | CA2693237A1 Composition and method for treatment of reperfusion injury and tissue damage |
| 02/12/2009 | CA2693095A1 Trazodone and trazodone hydrochloride in purified form |
| 02/12/2009 | CA2692837A1 Use of eflucimibe for the production of a medicament for the prevention or treatment of a disease caused by sebaceous gland dysfunction in humans or animals |
| 02/12/2009 | CA2691529A1 Quinoline compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor |
| 02/12/2009 | CA2691445A1 Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives |
| 02/12/2009 | CA2685740A1 Drug combinations for the treatment of duchenne muscular dystrophy |
| 02/12/2009 | CA2685002A1 Quinazoline compounds |
| 02/12/2009 | CA2666246A1 Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid |
| 02/11/2009 | EP2022853A1 Freeze-dried product for transferring nucleic acid, oligonucleic acid or derivative thereof |
| 02/11/2009 | EP2022796A1 Amorphous ciclesonide |
| 02/11/2009 | EP2022793A1 Novel heterocyclic compound or salt thereof and intermediate thereof |
| 02/11/2009 | EP2022790A1 A process for the preparation or purification of olmesartan medoxomil |
| 02/11/2009 | EP2022788A1 Novel crystal of 3-ý5-ý4-(cyclopentyloxy)-2- hydroxybenzoyl¨-2-ý(3-hydroxy-1,2-benzisoxazol-6- yl)methoxy¨phenyl¨propionic acid |
| 02/11/2009 | EP2022786A1 Anti-foot-and-mouth disease virus agent for animal belonging to family suidae or sheep, and method for prevention or treatment of foot-and-mouth disease in animal belonging to family suidae or sheep |